Halozyme updates leadership, COO departs
Halozyme Therapeutics, Inc. reported a senior leadership change.
Rhea-AI Filing Summary
Halozyme Therapeutics, Inc. reported a senior leadership change. On June 30, 2026, the company announced an update to its senior management structure and the departure of Cortney Caudill from her role as Senior Vice President and Chief Operating Officer. The company publicly expressed appreciation for Ms. Caudill’s contributions during her tenure.
Positive
- None.
Negative
- None.
Insights
Halozyme discloses COO departure as part of a management update.
Halozyme Therapeutics, Inc. announced an update to its senior management structure on June 30, 2026, including the departure of Senior Vice President and Chief Operating Officer Cortney Caudill. The company acknowledged her contributions, but the excerpt does not describe any replacement or restructuring details.
This type of leadership change can affect execution of operations, yet the information provided is limited to confirming her departure. There is no discussion of reasons, transition plans, or broader strategic shifts in this excerpt, so any impact assessment remains constrained to recognizing a disclosed change in a key operating role.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Management update announcement date: June 30, 2026
COO departure announcement date: June 30, 2026
Report signature date: July 2, 2026
3 metrics
Management update announcement date
June 30, 2026
Date Halozyme announced update to senior management structure
COO departure announcement date
June 30, 2026
Date company announced departure of Cortney Caudill
Report signature date
July 2, 2026
Date the 8-K was signed by the CFO
Key Terms
Section 13 or 15(d) of The Securities Exchange Act of 1934, Emerging growth company, Item 5.02. Departure of Directors or Certain Officers, Nasdaq Stock Market LLC
4 terms
Section 13 or 15(d) of The Securities Exchange Act of 1934 regulatory
"Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934"
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 5.02. Departure of Directors or Certain Officers regulatory
"Item 5.02. Departure of Directors or Certain Officers; Election of Directors"
Nasdaq Stock Market LLC financial
"Common Stock, $0.001 par value | HALO | The Nasdaq Stock Market LLC"
Nasdaq Stock Market LLC is the company that operates the Nasdaq electronic stock exchange, a large centralized marketplace where shares of publicly traded companies are listed and bought and sold. Think of it as a high-speed digital auction house and storefront combined: being listed there gives a company visibility and easier access to many buyers, while investors benefit from transparent prices, fast trades and regulated rules that help protect fair trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What management change did Halozyme Therapeutics (HALO) disclose in this 8-K?
Halozyme Therapeutics disclosed an update to its senior management structure, including the departure of Cortney Caudill as Senior Vice President and Chief Operating Officer, announced on June 30, 2026. The company thanked her for her contributions during her tenure.
Which executive is departing Halozyme Therapeutics (HALO) according to the filing?
The filing states that Cortney Caudill is departing Halozyme Therapeutics as Senior Vice President and Chief Operating Officer. Her departure was included within a broader update to the company’s senior management structure announced on June 30, 2026.
When did Halozyme Therapeutics (HALO) announce its senior management update?
Halozyme Therapeutics announced its senior management update on June 30, 2026. On that date, the company also announced the departure of Cortney Caudill from the role of Senior Vice President and Chief Operating Officer as part of the leadership changes.
Does the Halozyme Therapeutics (HALO) filing mention why the COO departed?
The filing does not provide a reason for Cortney Caudill’s departure. It simply notes that she is leaving her role as Senior Vice President and Chief Operating Officer and that the company expressed appreciation for her contributions during her tenure.
Who signed the Halozyme Therapeutics (HALO) 8-K reporting the management change?
The 8-K was signed on behalf of Halozyme Therapeutics by Darren Snellgrove, who is identified as Senior Vice President and Chief Financial Officer. His signature indicates the company’s formal submission of the report describing the management update and COO departure.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________
FORM 8-K
_____________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | ||||||||
(Exact name of registrant as specified in its charter)
________________________
Commission File Number 001-32335
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
| (Zip Code) | ||||||||
| (Address of principal executive offices) | ||||||||
(858 ) 794-8889
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(b) On June 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced an update to its senior management structure. The company also announced the departure of Cortney Caudill as the Company’s Senior Vice President, Chief Operating Officer. The Company would like to thank Ms. Caudill for her contributions during her tenure with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Halozyme Therapeutics, Inc. (Registrant) | |||||||||||||||||
Dated: | July 2, 2026 | By: | /s/ Darren Snellgrove | ||||||||||||||
| Darren Snellgrove | |||||||||||||||||
| Senior Vice President, Chief Financial Officer | |||||||||||||||||